The goal of the EL-PFDD virtual meeting on June 2, 2026, was to show the FDA and other decision makers how DS-AD impacts the lives of adults with Down syndrome and their families. Topics included the symptoms of DS-AD, individual experiences with available treatments, and hopes for future therapies. The insights shared during the EL-PFDD meeting will help inform future regulatory policies to better reflect the unique challenges that Alzheimer’s disease has on our community. Watch the recording below.
Thank you to our Sponsors!
